Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03909282 · ClinicalTrials.gov registry record · NA

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

A NA study of Ductal Breast Carcinoma in Situ, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT03909282 is a NA study of Ductal Breast Carcinoma in Situ that is actively recruiting participants, run by Stanford University. The registered enrollment target is 50 participants, below the 147-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03909282, a NA study of Ductal Breast Carcinoma in Situ, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)

Interventions

  • PROCEDURE Lumpectomy
  • RADIATION Partial breast irradiation prior to surgery

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-03-22
Est. Completion 2026-12
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT03909282

The ClinicalTrials.gov registry entry for NCT03909282 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 147-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (66% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ductal Breast Carcinoma in Situ appearing as the primary indexed condition, and to 2 interventions - of which Lumpectomy is the first listed.

NCT03909282 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03909282 about?

NCT03909282 is a clinical study titled "Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma". The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)

What is the current status of trial NCT03909282?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2019-03-22. Estimated completion is 2026-12.

What conditions does trial NCT03909282 study?

This clinical trial studies the following conditions: Ductal Breast Carcinoma in Situ.

What interventions are being tested in trial NCT03909282?

The interventions under investigation include: Lumpectomy (PROCEDURE), Partial breast irradiation prior to surgery (RADIATION).

Who is sponsoring clinical trial NCT03909282?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03909282 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ductal Breast Carcinoma in Situ

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.